Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
1305 East Houston Street , San Antonio, TX, 78205, US
Scorpius BioManufacturing is a U.S. biologics CDMO providing cGMP manufacturing, bioanalytical, and process development services for mammalian and microbial programs. Scorpius specializes in working with start-ups and emerging biotechs, giving small-volume programs the attention and flexibility they deserve.
As the number of new companies in biopharma continues to grow, so does their demand for outsourcing at every level of biopharmaceutical development.
Released By Scorpius BioManufacturing
A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.
What is a culture of quality, and how do you know if a biologics CDMO can earnestly make this claim?
Samir Lakhashe, Director, Bioanalytical Sciences, discusses assay categorization, the company's growing toolbox, predictions for the future, and more.
The demand for biologic drugs continues to grow at a steady 12–14% annually.
100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
Clinical manufacturing of cGMP-compliant mammalian cell culture processes is a complex and resource-intensive effort that presents several challenges.
Biologics process development is an active undertaking that seeks continuous improvement along the entire length of the drug development timeline.
A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle.
The value biologics CDMOs provide their innovator customers has changed radically in recent years, presenting new questions that must be answered.
The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.
When selecting a biologics CDMO partner—whether you need mammalian or microbial capabilities—the decision-making process follows a similar process.
Why Fina Biosolutions partnered with Scorpius Biomanufacturing for cGMP production of Ecocrm® (CRM197)
While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.
The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, and more.
Flexible, responsive, customized services for taking a program from R&D into the clinic, using American facilities and American sourced materials and equipment.
Delivering consistent and scalable mammalian-derived products, Scorpius uses its American facilities to advance your drug from R&D to the clinic and beyond.
Scorpius’ team has extensive experience in E. coli microbial biomanufacturing, including hard-to-work-with inclusion bodies.
Utilizing American-made equipment and reagents, Scorpius develops custom assays to profile your molecule and test your clinical trial samples.
Process development & cGMP contract manufacturing for biologics and cell therapies.
The Future of Oral Solids explores how innovation, advanced manufacturing, and integrated CDMO partnerships are reshaping the oral solid dosage (OSD) landscape, now and in the years ahead.
Released By Adare Pharma Solutions
Plans an expansion of its flagship biologics manufacturing facility in Frederick and construction of a new facility in Gaithersburg.
By: Charlie Sternberg
AGC Biologics to provide GMP manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss.
The strategic investment will help ensure all key Novartis medicines for U.S. patients are manufactured in the U.S. and delivered to patients across the country at scale.
David Basile of Hovione discusses expanded spray drying capacity in East Windsor and the benefits of integrated development, scale-up, and manufacturing at a single U.S. site.
Released By Hovione
Underscores the facility’s dedication to upholding the highest standards of quality across operations.
A conversation with Upperton’s Director of Pharmaceutical Sciences
Released By Upperton
The collaboration will leverage AGC Biologics' mRNA manufacturing knowledge and expertise to combat a leading cause of human mortality.
Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL).
Marks a strategic milestone in Halozyme’s mission to expand its drug delivery technology offerings to biopharma companies.
Strengthens its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics.
Expands the company’s nationwide network supporting cell and gene therapy (CGT) innovation.
This is the world’s first liquid formulation of IV infliximab and is available in 100 mg and 350 mg vials.
By: Rachel Klemovitch
Non-exclusive license provides Solid’s proprietary, next-gen capsid, AAV-SLB101, to Andelyn Biosciences.
Lee will head AdvanCell’s U.S. expansion, accelerating clinical, manufacturing, and partnership activities.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
